Health Canada approves Novocure's Optune to treat glioblastoma.

Optune is a medical device that works by creating Tumor Treating Fields (TTFields), which are electric fields that disrupt cancer cell division. Optune delivers TTFields therapy to the region of the tumor. Patients that used Optune plus temozolomide experienced overall survival of 20.9 months versus 16 months for patients treated with temozolomide alone.